MediWound Ltd. (NASDAQ:MDWD) Short Interest Down 30.6% in April

MediWound Ltd. (NASDAQ:MDWDGet Rating) was the target of a large decline in short interest in April. As of April 30th, there was short interest totalling 54,800 shares, a decline of 30.6% from the April 15th total of 79,000 shares. Approximately 0.3% of the company’s stock are sold short. Based on an average trading volume of 116,100 shares, the short-interest ratio is currently 0.5 days.

A number of institutional investors have recently added to or reduced their stakes in the business. Sargent Investment Group LLC raised its position in shares of MediWound by 2.5% during the first quarter. Sargent Investment Group LLC now owns 374,750 shares of the biopharmaceutical company’s stock valued at $746,000 after buying an additional 9,000 shares during the last quarter. Morgan Stanley raised its position in shares of MediWound by 12.4% during the third quarter. Morgan Stanley now owns 85,947 shares of the biopharmaceutical company’s stock valued at $287,000 after buying an additional 9,497 shares during the last quarter. Jane Street Group LLC acquired a new position in shares of MediWound during the third quarter valued at about $38,000. Goldman Sachs Group Inc. acquired a new position in shares of MediWound during the third quarter valued at about $48,000. Finally, Marshall Wace LLP acquired a new position in shares of MediWound during the first quarter valued at about $93,000. 13.58% of the stock is owned by hedge funds and other institutional investors.

MediWound stock traded down $0.03 on Friday, reaching $1.88. 46,220 shares of the stock were exchanged, compared to its average volume of 114,165. The stock has a market cap of $62.19 million, a PE ratio of -3.84 and a beta of 1.24. MediWound has a twelve month low of $1.25 and a twelve month high of $6.22. The firm has a fifty day moving average price of $2.02 and a two-hundred day moving average price of $2.41.

MediWound (NASDAQ:MDWDGet Rating) last released its earnings results on Thursday, March 17th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $5.49 million during the quarter, compared to analyst estimates of $5.65 million. MediWound had a negative net margin of 57.03% and a negative return on equity of 3,540.43%. During the same quarter in the previous year, the business earned ($0.06) EPS. Equities analysts anticipate that MediWound will post -0.39 EPS for the current fiscal year.

Several equities research analysts recently issued reports on the stock. Aegis reduced their price objective on shares of MediWound from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Monday, March 21st. StockNews.com assumed coverage on shares of MediWound in a research note on Friday. They issued a “sell” rating for the company. Finally, Zacks Investment Research lowered shares of MediWound from a “buy” rating to a “hold” rating in a research note on Saturday, March 19th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $5.69.

MediWound Company Profile (Get Rating)

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.

Featured Articles

Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.